Navigation Links
Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:
Date:1/24/2012

NEW BRUNSWICK, N.J., Jan. 24, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%. Domestic sales declined 3.4%, while international sales increased 10.2%, reflecting an operational increase of 10.4% and a negative currency impact of 0.2%. Worldwide sales for the full-year 2011 were $65.0 billion, an increase of 5.6% versus 2010. Operational sales increased 2.8% and the positive impact of currency was 2.8%.  Domestic sales declined 1.8%, while international sales increased 12.4%, reflecting operational growth of 7.0% and a positive currency impact of 5.4%.

Net earnings and diluted earnings per share for the fourth quarter of 2011 were $0.2 billion and $0.08, respectively. Fourth-quarter 2011 net earnings reflect after-tax charges of $2.9 billion, which include product liability expenses, the net impact of litigation settlements, costs associated with the DePuy ASR™ Hip recall program, and an adjustment to the value of a currency option and costs related to the planned acquisition of Synthes, Inc. Fourth-quarter 2010 net earnings included after-tax charges of $922 million representing product liability expenses, the net impact of litigation settlements, and costs associated with the DePuy ASR™ Hip recall program. Excluding these special items for both periods, net earnings for the current quarter were $3.1 billion and diluted earnings per share were $1.13, representing increases of 9.3% and 9.7%, respectively, as compared to the same period in 2010.*

Net earnings and diluted earnings per share for the full-year 2011 were $9.7 billion and $3.49, respectively. Full-year 2011 net earnings reflect after-tax charges of $4.2 billion, which include product liability expenses, the net impact of  litigation settlements, a previously announced restructuring charge by Cordis Corporation, costs associated with the DePuy ASR™ Hip recall program, and an adjustment to the value of a currency option and costs related to the planned acquisition of Synthes, Inc. Full-year 2010 net earnings included a net after-tax gain of $55 million representing product liability expenses, the net impact of litigation settlements, and costs associated with the DePuy ASR™ Hip recall program. Excluding these special items in both periods, net earnings for the full-year 2011 were $13.9 billion and diluted earnings per share were $5.00, representing increases of 4.4% and 5.0%, respectively, as compared with the full year of 2010.*The Company announced earnings guidance for full-year 2012 of $5.05 to $5.15 per share, which excludes the impact of special items. This guidance reflects operational growth of approximately 3.5% to 5.5% partially offset by an estimated negative impact of currency of approximately 2.5%.

"We delivered solid results for 2011, built on the strong growth of our recently launched pharmaceutical products, and continued the steady momentum of new product approvals across all our businesses," said William C. Weldon, Chairman and Chief Executive Officer.  "Our talented people are focused on bringing meaningful innovations to patients and customers to address significant unmet needs, positioning us well to deliver sustainable leadership and profitable growth in health care."

Worldwide Consumer sales of $14.9 billion for the full-year 2011 represented an increase of 2.0% over the prior year, consisting of an operational decline of 0.7% and a positive impact from currency of 2.7%. Domestic sales decreased 6.7%; international sales increased 7.3%, which reflected an operational increase of 2.9% and a positive currency impact of 4.4%.

Sales in U.S. over-the-counter medicines were significantly impacted by the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., as well as the impact on production volumes related to ongoing efforts to enhance quality and manufacturing systems.  Positive contributors to operational results were international sales of over-the-counter medicines; NEUTROGENA® skin care products; baby care products; and LISTERINE® antiseptic mouthrinse.Worldwide Pharmaceutical sales of $24.4 billion for the full-year 2011 represented an increase of 8.8% versus the prior year with an operational increase of 6.2% and a positive impact from currency of 2.6%. Domestic sales decreased 1.1%; international sales increased 21.3%, which reflected an operational increase of 15.5% and a positive currency impact of 5.8%.Sales results in the U.S. were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections, which was offset by the strong performance of recently launched products.

The strong performance of recently launched products include STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone or prednisolone, for the treatment of men with metastatic, castration-resistant prostate cancer; INVEGA® SUSTENNA® (paliperidone palmitate) a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults; and SIMPONI® (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. 

Also contributing to operational sales growth were strong results for REMICADE® (infliximab), a biologic approved for the treatment of a number of immune-mediated, inflammatory diseases, including incremental sales from the amended distribution agreement with Merck; recently acquired vaccines, proteins and antibodies from Crucell that prevent and/or treat infectious diseases; PREZISTA® (darunavir), a treatment for HIV; and VELCADE® (bortezomib), a treatment for multiple myeloma.

During the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for XARELTO® (rivaroxaban) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In addition, the European Commission granted marketing authorization for EDURANT® (rilpivirine) as a once daily treatment, in combination with other antiretroviral agents (ARVs), for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in ARV treatment-naive adult patients with a viral load < 100,000 HIV-1 RNA copies/mL.

Also during the quarter, supplemental New Drug Applications were submitted to the FDA seeking approval for the use of XARELTO® (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome, and for NUCYNTA® ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults. The Company also announced an agreement with Pharmacyclics, Inc. to jointly develop and market the BTK Inhibitor, PCI-32765, for the treatment of cancer.

Worldwide Medical Devices and Diagnostics sales of $25.8 billion for the full-year 2011 represented an increase of 4.8% versus the prior year with an operational increase of 1.7% and a positive impact from currency of 3.1%. Domestic sales decreased 0.4%; international sales increased 9.2%, which reflected an operational increase of 3.4% and a positive currency impact of 5.8%.Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's Advanced Sterilization Products and international sales of minimally invasive products; Diabetes Care's blood glucose monitoring and insulin delivery products; Biosense Webster's electrophysiology business; and Vistakon's disposable contact lenses. This growth was partially offset by lower sales in the Cardiovascular Care business, reflecting continued market and competitive pressures. As the Company previously announced, we have now exited the drug eluting stent market.

During the quarter, the FDA approved the new ThermoCool® SF irrigated ablation catheter for use in atrial fibrillation and cleared the ENSEAL® G2 Curved and Straight Tissue Sealers to expand surgeons' options for achieving strong vessel seals in both open and minimally invasive surgery. Ethicon Endo-Surgery, Inc. also completed its acquisition of SterilMed, Inc., a leader in the reprocessing and remanufacturing of single-use medical devices in the United States.

About Johnson & JohnsonCaring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 118,000 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's investor website at www.jnj.com

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)Johnson & Johnson and Subsidiaries 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Supplementary Sales Data 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 (Unaudited; Dollars in Millions)

 FOURTH QUARTER TWELVE MONTHS 

 

 

 

 

 

 

Percent Change

 

 

 

 

 

 

 

 

Percent Change

 

  2011 

 2010 

Total

 

Operations

 

Currency

 2011 2010 

Total

 

Operations

 

CurrencySales to customers by 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 segment of business 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Consumer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 U.S.$
,248 

 1,219 

2.4

%

2.4

 

-

 $
5,151 5,519 

(6.7)

%

(6.7)

 

-International2,420 

 2,391 

1.2

 

2.8

 

(1.6)

 9,732 9,071 

7.3

 

2.9

 

4.4 3,668 

 3,610 

1.6

 

2.7

 

(1.1)

 14,883 14,590 

2.0

 

(0.7)

 

2.7 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Pharmaceutical

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 U.S.2,887 

 3,149 

(8.3)

 

(8.3)

 

-

 12,386 12,519 

(1.1)

 

(1.1)

 

-International3,207 

 2,561 

25.2

 

25.0

 

0.2

 11,982 9,877 

21.3

 

15.5

 

5.8 6,094 

 5,710 

6.7

 

6.6

 

0.1

 24,368 22,396 

8.8

 

6.2

 

2.6 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Med Devices & Diagnostics

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 U.S.2,850 

 2,861 

(0.4)

 

(0.4)

 

-

 11,371 11,412 

(0.4)

 

(0.4)

 

-International3,643 

 3,463 

5.2

 

4.6

 

0.6

 14,408 13,189 

9.2

 

3.4

 

5.8 6,493 

 6,324 

2.7

 

2.4

 

0.3

 25,779 24,601 

4.8

 

1.7

 

3.1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 U.S.6,985 

 7,229 

(3.4)

 

(3.4)

 

-

 28,908 29,450 

(1.8)

 

(1.8)

 

-International9,270 

 8,415 

10.2

 

10.4

 

(0.2)

 36,122 32,137 

12.4

 

7.0

 

5.4Worldwide$
,255 

 15,644 

3.9

%

4.0

 

(0.1)

 $
5,030 61,587 

5.6

%

2.8

 

2.8 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Johnson & Johnson and Subsidiaries 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Supplementary Sales Data 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 (Unaudited; Dollars in Millions)FOURTH QUARTER TWELVE MONTHS 

 

 

 

 

 

Percent Change

 

 

 

 

 

 

 

 

Percent Change

 

  2011 2010 

Total

 

Operations

 

Currency

 2011 2010 

Total

 

Operations

 

CurrencySales to customers by 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 geographic area 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 U.S.$
,985 7,229 

(3.4)

%

(3.4)

 

-

 $   28,908 29,450 

(1.8)

%

(1.8)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Europe4,279 3,947 

8.4

 

9.4

 

(1.0)

 17,129 15,510 

10.4

 

5.3

 

5.1Western Hemisphere excluding U.S.1,688 1,471 

14.8

 

17.8

 

(3.0)

 6,418 5,550 

15.6

 

12.2

 

3.4Asia-Pacific, Africa3,303 2,997 

10.2

 

7.9

 

2.3

 12,575 11,077 

13.5

 

6.6

 

6.9International9,270 8,415 

10.2

 

10.4

 

(0.2)

 36,122 32,137 

12.4

 

7.0

 

5.4 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Worldwide$   16,255 15,644 

3.9

%

4.0

 

(0.1)

 $   65,030 61,587 

5.6

%

2.8

 

2.8 

 

 

 

 

 

 

 

 

  

 

 

Johnson & Johnson and Subsidiaries 

 

 

 

 

 

 

 

 Condensed Consolidated Statement of Earnings 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 (Unaudited; in Millions Except Per Share Figures)FOURTH QUARTER 

 

 

 

 

 

 

 

 

  2011 2010 

Percent 

 

 Percent 

 

 Percent 

Increase Amount to Sales Amount to Sales 

(Decrease)Sales to customers$ 16,255 100.0 $ 15,644 100.0 

3.9Cost of products sold5,338 32.8 5,040 32.2 

5.9Selling, marketing and administrative expenses5,458 33.6 5,180 33.1 

5.4Research and development expense2,155 13.3 1,982 12.7 

8.7Interest (income)expense, net148 0.9 114 0.7 

 Other (income)expense, net2,858 17.6 1,100 7.1 

 Restructuring (income)expense, net(20) (0.1) - - 

 Earnings before provision for taxes on income318 1.9 2,228 14.2 

(85.7)Provision for taxes on income100 0.6 286 1.8 

(65.0)Net earnings$
218 1.3 $   1,942 12.4 

(88.8) 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 Net earnings per share  (Diluted)$
.08 

 

 $
.70 

 

 

(88.6) 

 

 

 

 

 

 

 

 

 Average shares outstanding  (Diluted)2,768.9 

 

 2,781.6 

 

 

  

 

 

 

 

 

 

 

 

 Effective tax rate31.4% 

 12.8% 

 

  

 

 

 

 

 

 

 

 

 Adjusted earnings before provision for taxes and net earnings 

 

 

 

 

 

 

 

 
Earnings before provision for taxes on income
$   3,657(1)22.5 $   3,451(1)22.1 

6.0
Net earnings
$   3,129(1)19.2 $   2,864(1)18.3 

9.3
Net earnings per share  (Diluted)
$
.13(1) 

 $
.03(1) 

 

9.7
Effective tax rate
14.4% 

 

 17.0% 

 

 

  

 

 

 

 

 

 

 

 

 (1)  See Reconciliation of Non-GAAP Financial Measures. 

 

 

 

 

 

 

 

 

 Johnson & Johnson and Subsidiaries 

 

 

 

 

 

 

 

 Condensed Consolidated Statement of Earnings 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 (Unaudited; in Millions Except Per Share Figures)TWELVE MONTHS 

 

 

 

 

 

 

 

 

  2011 2010 

Percent 

 

 Percent 

 

 Percent 

Increase Amount to Sales Amount to Sales 

(Decrease)Sales to customers$ 65,030 100.0 $ 61,587 100.0 

5.6Cost of products sold20,360 31.3 18,792 30.5 

8.3Selling, marketing and administrative expenses20,969 32.3 19,424 31.5 

8.0Research and development expense7,548 11.6 6,844 11.1 

10.3Interest (income)expense, net480 0.7 348 0.6 

 Other (income)expense, net2,743 4.2 (768) (1.2) 

 Restructuring (income)expense, net569 0.9 - - 

 Earnings before provision for taxes on income12,361 19.0 16,947 27.5 

(27.1)Provision for taxes on income2,689 4.1 3,613 5.8 

(25.6)Net earnings$   9,672 14.9 $ 13,334 21.7 

(27.5) 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 Net earnings per share  (Diluted)$
3.49 

 

 $
4.78 

 

 

(27.0) 

 

 

 

 

 

 

 

 

 Average shares outstanding  (Diluted)2,775.3 

 

 2,788.8 

 

 

  

 

 

 

 

 

 

 

 

 Effective tax rate21.8% 

 21.3% 

 

  

 

 

 

 

 

 

 

 

 Adjusted earnings before provision for taxes and net earnings 

 

 

 

 

 

 

 

 
Earnings before provision for taxes on income
$ 17,353(1)26.7 $ 16,830(1)27.3 

3.1
Net earnings
$ 13,867(1)21.3 $ 13,279(1)21.6 

4.4
Net earnings per share  (Diluted)
$
5.00(1) 

 $
4.76(1) 

 

5.0
Effective tax rate
20.1% 

 

 21.1% 

 

 

  

 

 

 

 

 

 

 

 

 (1)  See Reconciliation of Non-GAAP Financial Measures. 

 

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)  FOURTH QUARTER TWELVE MONTHS 

 

 % Change 

 

 % Change 20112010ReportedOperational (1)Currency 20112010ReportedOperational (1)CurrencyCONSUMER SEGMENT (2) 

 

 

 

 

 

 

 

 

 

 BABY CARE

 

 

 

 

 

 

 

 

 

 

 US1031030.0%

0.0%

-

 4184092.2%

2.2%

-Intl465474-1.9%

0.7%

-2.6%

 1,9221,8006.8%

3.4%

3.4%WW568577-1.6%

0.6%

-2.2%

 2,3402,2095.9%

3.2%

2.7%ORAL CARE

 

 

 

 

 

 

 

 

 

 

 US17314916.1%

16.1%

-

 6566353.3%

3.3%

-Intl239240-0.4%

1.4%

-1.8%

 9688918.6%

3.9%

4.7%WW4123895.9%

7.0%

-1.1%

 1,6241,5266.4%

3.6%

2.8%OTC/NUTRITIONALS

 

 

 

 

 

 

 

 

 

 

 US370381-2.9%

-2.9%

-

 1,4291,853-22.9%

-22.9%

-Intl7667117.7%

8.7%

-1.0%

 2,9732,69610.3%

5.2%

5.1%WW1,1361,0924.0%

4.6%

-0.6%

 4,4024,549-3.2%

-6.2%

3.0%SKIN CARE

 

 

 

 

 

 

 

 

 

 

 US40335214.5%

14.5%

-

 1,6541,5377.6%

7.6%

-Intl5415370.7%

1.3%

-0.6%

 2,0611,9157.6%

3.0%

4.6%WW9448896.2%

6.6%

-0.4%

 3,7153,4527.6%

5.0%

2.6%WOMEN'S HEALTH

 

 

 

 

 

 

 

 

 

 

 US89118-24.6%

-24.6%

-

 439522-15.9%

-15.9%

-Intl309332-6.9%

-4.0%

-2.9%

 1,3531,3222.3%

-1.5%

3.8%WW398450-11.6%

-9.5%

-2.1%

 1,7921,844-2.8%

-5.5%

2.7%WOUND CARE/OTHER

 

 

 

 

 

 

 

 

 

 

 US110116-5.2%

-5.2%

-

 555563-1.4%

-1.4%

-Intl100973.1%

6.2%

-3.1%

 4554471.8%

-3.3%

5.1%WW210213-1.4%

-0.5%

-0.9%

 1,0101,0100.0%

-2.3%

2.3%TOTAL CONSUMER 

 

 

 

 

 

 

 

 

 

 US1,2481,2192.4%2.4%- 5,1515,519-6.7%-6.7%-Intl2,4202,3911.2%2.8%-1.6% 9,7329,0717.3%2.9%4.4%WW3,6683,6101.6%2.7%-1.1% 14,88314,5902.0%-0.7%2.7% 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 See footnotes at end of schedule

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)  FOURTH QUARTER TWELVE MONTHS 

 

 % Change 

 

 % Change 20112010ReportedOperational (1)Currency 20112010ReportedOperational (1)CurrencyPHARMACEUTICAL SEGMENT  (2) (4) 

 

 

 

 

 

 

 

 

 

 ACIPHEX/PARIET

 

 

 

 

 

 

 

 

 

 

 US110119-7.6%

-7.6%

-

 414475-12.8%

-12.8%

-Intl1441338.3%

8.7%

-0.4%

 5615315.6%

0.0%

5.6%WW2542520.8%

1.0%

-0.2%

 9751,006-3.1%

-6.1%

3.0%CONCERTA/METHYLPHENIDATE

 

 

 

 

 

 

 

 

 

 

 US155261-40.6%

-40.6%

-

 822929-11.5%

-11.5%

-Intl11910711.2%

11.6%

-0.4%

 44639014.4%

8.7%

5.7%WW274368-25.5%

-25.4%

-0.1%

 1,2681,319-3.9%

-5.6%

1.7%DOXIL/CAELYX

 

 

 

 

 

 

 

 

 

 

 US1055-81.8%

-81.8%

-

 140280-50.0%

-50.0%

-Intl2912*

*

-10.3%

 26240*

*

5.3%WW3967-41.8%

-34.1%

-7.7%

 40232025.6%

22.1%

3.5%DURAGESIC/FENTANYL TRANSDERMAL

 

 

 

 

 

 

 

 

 

 

 US2145-53.3%

-53.3%

-

 90162-44.4%

-44.4%

-Intl119151-21.2%

-21.9%

0.7%

 499586-14.8%

-20.1%

5.3%WW140196-28.6%

-29.1%

0.5%

 589748-21.3%

-25.5%

4.2%LEVAQUIN/FLOXIN

 

 

 

 

 

 

 

 

 

 

 US(6)386*

*

-

 5791,312-55.9%

-55.9%

-Intl1114-21.4%

-17.7%

-3.7%

 4445-2.2%

-3.7%

1.5%WW5400-98.8%

-98.7%

-0.1%

 6231,357-54.1%

-54.2%

0.1%PREZISTA

 

 

 

 

 

 

 

 

 

 

 US14311128.8%

28.8%

-

 52940131.9%

31.9%

-Intl17312538.4%

39.0%

-0.6%

 68245649.6%

44.8%

4.8%WW31623633.9%

34.2%

-0.3%

 1,21185741.3%

38.6%

2.7%PROCRIT/EPREX

 

 

 

 

 

 

 

 

 

 

 US191270-29.3%

-29.3%

-

 8141,070-23.9%

-23.9%

-Intl177209-15.3%

-13.7%

-1.6%

 809864-6.4%

-10.8%

4.4%WW368479-23.2%

-22.6%

-0.6%

 1,6231,934-16.1%

-18.0%

1.9%REMICADE

 

 

 

 

 

 

 

 

 

 

 US 77667914.3%

14.3%

-

 3,2763,0995.7%

5.7%

-US Exports (3)43738114.7%

14.7%

-

 1,7971,48720.8%

20.8%

-Intl2155*

*

2.3%

 41924*

*

4.8%WW1,4281,06534.1%

33.6%

0.5%

 5,4924,61019.1%

18.7%

0.4%RISPERDAL/RISPERIDONE 

 

 

 

 

 

 

 

 

 

 

 US72*

*

-

 34(12)*

*

-Intl141149-5.4%

-7.9%

2.5%

 508539-5.8%

-11.6%

5.8%WW148151-2.0%

-4.4%

2.4%

 5425272.8%

-3.1%

5.9%RISPERDAL CONSTA

 

 

 

 

 

 

 

 

 

 

 US1081052.9%

2.9%

-

 443445-0.4%

-0.4%

-Intl277283-2.1%

-1.3%

-0.8%

 1,1401,0558.1%

2.7%

5.4%WW385388-0.8%

-0.2%

-0.6%

 1,5831,5005.5%

1.7%

3.8%TOPAMAX

 

 

 

 

 

 

 

 

 

 

 US40378.1%

8.1%

-

 176199-11.6%

-11.6%

-Intl8184-3.6%

-2.6%

-1.0%

 312339-8.0%

-11.9%

3.9%WW1211210.0%

0.7%

-0.7%

 488538-9.3%

-11.8%

2.5%VELCADE

 

 

 

 

 

 

 

 

 

 

 US

-

-

-

-

-

 

-

-

-

-

-Intl35228722.6%

22.4%

0.2%

 1,2741,08018.0%

12.7%

5.3%WW35228722.6%

22.4%

0.2%

 1,2741,08018.0%

12.7%

5.3%OTHER

 

 

 

 

 

 

 

 

 

 

 US89569828.2%

28.2%

-

 3,2722,67222.5%

22.5%

-Intl1,3691,00236.6%

36.0%

0.6%

 5,0263,92828.0%

22.2%

5.8%WW2,2641,70033.2%

32.8%

0.4%

 8,2986,60025.7%

22.2%

3.5%TOTAL PHARMACEUTICAL 

 

 

 

 

 

 

 

 

 

 US2,8873,149-8.3%-8.3%- 12,38612,519-1.1%-1.1%-Intl3,2072,56125.2%25.0%0.2% 11,9829,87721.3%15.5%5.8%WW6,0945,7106.7%6.6%0.1% 24,36822,3968.8%6.2%2.6% 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 See footnotes at end of schedule

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  REPORTED SALES vs. PRIOR PERIOD ($MM) 

  

 

 

 

 

 

 

 

 

 

 

  FOURTH QUARTER 

 

 TWELVE MONTHS 

  

 

 Total 

 

 

 

 Total 

 MAJOR NEW PHARM PRODUCTS(4)20112010% Change 

 

 20112010% Change 

 (INCLUDED IN OTHER) 

 

 

 

 

 

 

 

 

 

 INTELENCE

 

 

 

 

 

 

 

 

 

 

 US453432.4%

 

 

 16312728.3%

 

 Intl383122.6%

 

 

 15111630.2%

 

 WW836527.7%

 

 

 31424329.2%

 

 INVEGA

 

 

 

 

 

 

 

 

 

 

 US6670-5.7%

 

 

 2852705.6%

 

 Intl594628.3%

 

 

 21415439.0%

 

 WW1251167.8%

 

 

 49942417.7%

 

 SIMPONI

 

 

 

 

 

 

 

 

 

 

 US625610.7%

 

 

 23519321.8%

 

 Intl579*

 

 

 17533*

 

 WW1196583.1%

 

 

 41022681.4%

 

 STELARA

 

 

 

 

 

 

 

 

 

 

 US1267372.6%

 

 

 44324084.6%

 

 Intl814772.3%

 

 

 29515392.8%

 

 WW20712072.5%

 

 

 73839387.8%

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 See footnotes at end of schedule

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM) 

 

  FOURTH QUARTER TWELVE MONTHS 

 

 % Change 

 

 % Change 20112010ReportedOperational (1)Currency 20112010ReportedOperational (1)CurrencyMEDICAL DEVICES AND DIAGNOSTICS
(2) 

 

 

 

 

 

 

 

 

 

 CARDIOVASCULAR CARE (5)

 

 

 

 

 

 

 

 

 

 

 US191246-22.4%

-22.4%

-

 8411,008-16.6%

-16.6%

-Intl349383-8.9%

-9.6%

0.7%

 1,4471,544-6.3%

-11.4%

5.1%WW540629-14.1%

-14.5%

0.4%

 2,2882,552-10.3%

-13.4%

3.1%DEPUY

 

 

 

 

 

 

 

 

 

 

 US775807-4.0%

-4.0%

-

 3,0933,145-1.7%

-1.7%

-Intl6786405.9%

5.7%

0.2%

 2,7162,44011.3%

5.0%

6.3%WW1,4531,4470.4%

0.3%

0.1%

 5,8095,5854.0%

1.2%

2.8%DIABETES CARE

 

 

 

 

 

 

 

 

 

 

 US3303183.8%

3.8%

-

 1,3121,2594.2%

4.2%

-Intl3403264.3%

4.4%

-0.1%

 1,3401,21110.7%

5.7%

5.0%WW6706444.0%

4.1%

-0.1%

 2,6522,4707.4%

5.0%

2.4%ETHICON

 

 

 

 

 

 

 

 

 

 

 US5365017.0%

7.0%

-

 2,1112,0005.6%

5.6%

-Intl6976517.1%

7.6%

-0.5%

 2,7592,50310.2%

5.0%

5.2%WW1,2331,1527.0%

7.3%

-0.3%

 4,8704,5038.2%

5.3%

2.9%ETHICON ENDO-SURGERY

 

 

 

 

 

 

 

 

 

 

 US5245014.6%

4.6%

-

 1,9571,975-0.9%

-0.9%

-Intl8097567.0%

6.3%

0.7%

 3,1232,78312.2%

6.3%

5.9%WW1,3331,2576.0%

5.6%

0.4%

 5,0804,7586.8%

3.4%

3.4%ORTHO-CLINICAL DIAGNOSTICS

 

 

 

 

 

 

 

 

 

 

 US2802761.4%

1.4%

-

 1,0911,0910.0%

0.0%

-Intl2742605.4%

4.8%

0.6%

 1,07396211.5%

5.9%

5.6%WW5545363.4%

3.1%

0.3%

 2,1642,0535.4%

2.8%

2.6%VISION CARE

 

 

 

 

 

 

 

 

 

 

 US2142120.9%

0.9%

-

 9669343.4%

3.4%

-Intl49644711.0%

8.2%

2.8%

 1,9501,74611.7%

4.5%

7.2%WW7106597.7%

5.8%

1.9%

 2,9162,6808.8%

4.1%

4.7%TOTAL MEDICAL DEVICES AND DIAGNOSTICS 

 

 

 

 

 

 

 

 

 

 US2,8502,861-0.4%-0.4%- 11,37111,412-0.4%-0.4%-Intl3,6433,4635.2%4.6%0.6% 14,40813,1899.2%3.4%5.8%WW6,4936,3242.7%2.4%0.3% 25,77924,6014.8%1.7%3.1% 

 

 

 

 

 

 

 

 

 

 

 * Percentage greater than 100%

 

 

 

 

 

 

 

 

 

 

 (1) Operational growth excludes the effect of currency

 

 

 

 

 

 

 

 (2) Select areas (unaudited)

 

 

 

 

 

 

 

 

 

 

 (3) Reported in U.S. sales

 

 

 

 

 

 

 

 

 

 

 (4) Prior year amounts have been reclassified to conform to current year product disclosure

 

 

 

 

 

 (5) Previously Cordis

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Johnson & Johnson and Subsidiaries 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Reconciliation of Non-GAAP Financial Measures 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

Fourth Quarter

 

% Incr. /

 

 

Twelve Months 

 

% Incr. /

 (Dollars in Millions Except Per Share Data)

 

 

 

2011

 

2010

 

(Decr.)

 

 

2011

 

2010

 

(Decr.)

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Earnings before provision for taxes on income - as reported

 

 

 

$
318

 

2,228

 

(85.7)

%

 

$ 12,361

 

16,947

 

(27.1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Net litigation settlements loss (gain)

 

 

 

1,134

 

374

 

 

 

 

1,710

 

(966)

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Product liability expenses

 

 

 

1,522

 

569

 

 

 

 

1,600

 

569

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Restructuring 

 

 

 

(20)

 

-

 

 

 

 

656

 

-

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 DePuy ASR Hip recall program

 

 

 

412

 

280

 

 

 

 

521

 

280

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Currency option adjustment and costs related to planned acquisition of Synthes

 

 

 

277

 

-

 

 

 

 

491

 

-

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 In-process research and development

 

 

 

14

 

-

 

 

 

 

14

 

-

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Earnings before provision for taxes on income - as adjusted

 

 

 

$ 3,657

 

3,451

 

6.0

%

 

$ 17,353

 

16,830

 

3.1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Net Earnings - as reported

 

 

 

$
218

 

1,942

 

(88.8)

%

 

$   9,672

 

13,334

 

(27.5)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Net litigation settlements loss (gain)

 

 

 

1,022

 

279

 

 

 

 

1,466

 

(698)

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Product liability expenses

 

 

 

1,217

 

404

 

 

 

 

1,279

 

404

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Restructuring 

 

 

 

(13)

 

-

 

 

 

 

536

 

-

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 DePuy ASR Hip recall program

 

 

 

336

 

239


'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
3. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
4. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
5. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
6. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
7. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
8. EF Johnson Technologies Announces Third Quarter Results
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):